Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JNJ

Johnson & Johnson

Sep 12 • 04:00PM ET

178.06

-0.44 -0.25 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM DGRO QUAL

Scroll to Statements

Index	DJIA, S&P 500	P/E	19.04	EPS (ttm)	9.35	Insider Own	0.13%	Shs Outstand	2.41B	Perf Week	-0.21%
Market Cap	428.83B	Forward P/E	15.68	EPS next Y	11.35	Insider Trans	-6.52%	Shs Float	2.41B	Perf Month	2.09%
Enterprise Value	460.71B	PEG	2.88	EPS next Q	2.75	Inst Own	74.00%	Short Float	0.78%	Perf Quarter	13.66%
Income	22.66B	P/S	4.73	EPS this Y	8.75%	Inst Trans	0.61%	Short Ratio	2.23	Perf Half Y	9.25%
Sales	90.62B	P/B	5.46	EPS next Y	4.62%	ROA	12.10%	Short Interest	18.84M	Perf YTD	23.12%
Book/sh	32.60	P/C	22.71	EPS next 5Y	6.61%	ROE	30.21%	52W High	181.16 -1.71%	Perf Year	6.38%
Cash/sh	7.84	P/FCF	23.12	EPS past 3/5Y	-9.49% 0.55%	ROIC	19.25%	52W Low	140.68 26.57%	Perf 3Y	8.53%
Dividend Est.	5.06 (2.84%)	EV/EBITDA	15.76	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.12%	Volatility	1.36% 1.25%	Perf 5Y	19.83%
Dividend TTM	5.08 (2.85%)	EV/Sales	5.08	EPS Y/Y TTM	34.88%	Oper. Margin	24.02%	ATR (14)	2.38	Perf 10Y	92.21%
Dividend Ex-Date	Aug 26, 2025	Quick Ratio	0.76	Sales Y/Y TTM	4.69%	Profit Margin	25.01%	RSI (14)	59.85	Recom	2.23
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.01	EPS Q/Q	18.30%	SMA20	0.24%	Beta	0.39	Target Price	178.20
Payout	84.80%	Debt/Eq	0.65	Sales Q/Q	5.76%	SMA50	4.50%	Rel Volume	0.85	Prev Close	178.50
Employees	139800	LT Debt/Eq	0.50	Earnings	Jul 16 BMO	SMA200	12.65%	Avg Volume	8.44M	Price	178.06
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.29% 3.89%	Trades		Volume	7,214,885	Change	-0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173

Show Previous Ratings

Sep-12-25 12:11PM	Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most. (Barrons.com)
11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
09:21AM	AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock (Zacks)
09:08AM	Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? (Zacks)
08:45AM	India's Vadilal Industries U.S. unit to make ice creams locally to cut imports (Reuters)
08:53PM	Loading…
Sep-11-25 08:53PM	This year healthcare is the worst performing part of the market by far, says Jim Cramer (CNBC TV)
08:53PM	After a couple years in purgatory, Johnson & Johnson is now having a strong year, says Jim Cramer (CNBC TV)
05:45PM	Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
03:43PM	Prescription Drug Ads Could Be Changing. These Stocks Could Get Hurt the Most. (Barrons.com)
01:30PM	Warren Buffett wouldnt worry about cash if he retired with just $1M heres why and how to copy his strategy (Moneywise)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
04:25AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer (Zacks)
Sep-10-25 02:41PM	Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery (Benzinga)
12:12PM	Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales. (Barrons.com)
11:08AM	5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds (Zacks)
11:02AM	Loading…
11:02AM	J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum (Zacks)
10:05AM	The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries (Zacks)
08:56AM	Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG? (Zacks)
05:13AM	J&J obtains FDA approval for gemcitabine intravesical system (Medical Device Network)
04:00AM	Pharmas new boomtown? Why drugmakers are setting up shop in a small Swiss city. (Pharma Voice)
12:10AM	Jim Cramer on Johnson & Johnson: "Their Core Pharma Business is Roaring" (Insider Monkey)
Sep-09-25 04:45PM	Tylenol makers stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a major overreaction (Fortune)
04:41PM	Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola (Zacks)
04:18PM	U.S. FDA approval of INLEXZO (gemcitabine intravesical system) set to transform how certain bladder cancers are treated (PR Newswire)
11:45AM	Are You Looking for a High-Growth Dividend Stock? (Zacks)
11:34AM	LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal (Zacks)
08:50AM	Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds? (Zacks)
04:49AM	AHA accuses drug companies of colluding to impose 340B rebate plans (Healthcare Dive)
Sep-08-25 06:17PM	Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors (Business Wire)
04:25PM	Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum (Business Wire)
11:48AM	Loading…
11:48AM	A new class of sleep drugs draws Wall Streets attention (BioPharma Dive)
09:15AM	J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? (Zacks)
07:41AM	Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus (Zacks)
06:11AM	Ronovo Surgical raises $67M, led by J&J venture arm (MedTech Dive)
Sep-07-25 03:22AM	Data published in The New England Journal of Medicine demonstrate RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer (PR Newswire)
Sep-06-25 07:00PM	Johnson & Johnson: A 6.9 Rating and What It Means for Investors (Motley Fool)
06:42AM	3 Stocks to Buy and Hold Forever (Motley Fool)
03:00AM	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer (PR Newswire)
Sep-05-25 04:25PM	Analyst Report: Kenvue Inc. (Morningstar Research)
03:16PM	Tylenol maker Kenvue's stock heads for a record selloff after troubling WSJ report (MarketWatch)
03:04PM	Kenvue Stock Tumbles on Report Kennedy Will Link Autism and Tylenol (Barrons.com)
10:53AM	BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth? (Zacks)
Sep-04-25 10:46AM	Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX? (Zacks)
09:17AM	Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? (Zacks)
06:00AM	Kardium receives FDA OK for pulsed field ablation system (MedTech Dive)
04:09AM	Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? (Motley Fool)
Sep-03-25 04:29PM	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results (Business Wire)
02:09PM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
10:04AM	J&J Gears Up for Some Key New Drug Approvals and Launches (Zacks)
07:00AM	3 medtech takeaways from ESC 2025 (MedTech Dive)
03:52AM	Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats (Pharma Voice)
Sep-02-25 03:53PM	Johnson & Johnson Scores With Heart Pump Breakthrough (GuruFocus.com)
10:10AM	Glaukos Builds Dual Growth Engines Amid Market Headwinds (Zacks)
10:01AM	Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales (Zacks)
08:40AM	J&J publishes new data from DanGer Shock randomized control trial (TipRanks)
08:00AM	Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE Platform, at 2025 European Society of Cardiology (ESC) Congress (PR Newswire)
03:27AM	Johnson & Johnson (JNJ)'s Carvykti Sales Skyrocket 100% Amid Specialty Medicine Growth (Insider Monkey)
Aug-31-25 02:10PM	These 4 Dividend Stocks Are Money-Printing Machines (Motley Fool)
12:15PM	New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump (PR Newswire)
08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-29-25 04:24PM	Earnings Season Highlights on Tariffs, Consumer Spending, and More (Barrons.com)
03:12PM	Johnson & Johnson Ends RA Combo After Mid-Stage Miss (GuruFocus.com)
11:13AM	J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure (Zacks)
10:17AM	ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025? (Zacks)
09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:21AM	Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program (Benzinga)
02:53AM	How Is Johnson & Johnsons Stock Performance Compared to Other Healthcare Stocks? (Barchart)
Aug-28-25 03:32PM	These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth (Barchart)
03:17PM	Commentary: Trumps trade war is hurting most sectors of the economy (Yahoo Finance)
02:41PM	Healthcare Stocks Are 'Priced at Panic Levels.' It's Time to Buy. (Barrons.com)
11:30AM	Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? (Zacks)
09:22AM	Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds? (Zacks)
08:00AM	AMDR Applauds Federal Court Decision to Bar Johnson & Johnson's Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment (Business Wire)
07:11AM	J&J removes some Abiomed heart pump controllers from market (MedTech Dive)
Aug-27-25 11:17AM	What Is the Intent Behind AbbVie's Recent Acquisition Spree? (Zacks)
10:05AM	Will Camzyos Strengthen BMY's Cardiovascular Portfolio? (Zacks)
Aug-26-25 11:53PM	Citi Lifts Johnson & Johnson (JNJ) Price Target to $200 on MedTech Strength (Insider Monkey)
09:35AM	As the Market Rotates, This Healthcare ETF Is Leading the Way (MarketBeat)
08:08AM	ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression (Zacks)
07:54AM	J&J earmarks $2B for Fujifilms North Carolina facility (Manufacturing Dive)
Aug-25-25 11:55PM	Johnson & Johnson to Invest $2 Billion in New North Carolina Facility (Insider Monkey)
10:20AM	Take the Zacks Approach to Beat the Markets: WisdomTree, SkyWest & PepsiCo in Focus (Zacks)
08:39AM	J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy? (Zacks)
07:44AM	5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones (Zacks)
07:41AM	3 Dividend Growth Leaders to Buy Now (MarketBeat)
07:27AM	JNJ Stock Surge Signals Confidence in New Growth Path (MarketBeat)
04:04AM	Got $500? 3 Dividend Stocks to Buy and Hold Forever (Motley Fool)
Aug-24-25 11:14AM	2 Dividend Stocks Worth Doubling Down on Right Now (Motley Fool)
01:22AM	Johnson & Johnson (JNJ) Becomes Sector Gamma AS's 6th-Largest Holding (Insider Monkey)
Aug-22-25 11:45AM	Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now (Zacks)
10:45AM	Stock Market Today: Stocks surge after Fed's Powell hints on rates (TheStreet)
09:53AM	Stryker's Robotics and Global Gains Offset by Macro Concerns (Zacks)
08:02AM	4 Medical Devices Behemoths to Buy Amid Extensive AI Applications (Zacks)
08:00AM	Investors Crave Long-Term Debt, But Firms Dont Want to Sell (Bloomberg)
Aug-21-25 06:32PM	3 Stable Dividend-Paying Stocks That Are Perfect for Retirees (Motley Fool)
02:49PM	Johnson & Johnson Shares Rally as Pharma Giant Invests $2 Billion in U.S. Expansion (GuruFocus.com)
11:58AM	J&J signs $2bn incumbency deal at CDMO Fujifilms new hub (Pharmaceutical Technology)
11:32AM	US-EU trade deal impacts on pharma industry more 'manageable' than expected (Yahoo Finance)
09:18AM	Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds? (Zacks)
08:21AM	Johnson & Johnson, WH Smith, and Disney: Trending stocks (Yahoo Finance Video)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Option Exercise	101.87	56,471	5,752,701	234,484	Sep 05 06:00 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Sep 04 '25	Sale	177.81	56,471	10,040,883	178,013	Sep 05 06:00 PM
Taubert Jennifer L	Officer	Sep 04 '25	Proposed Sale	177.81	56,471	10,040,904		Sep 04 02:37 PM
Forminard Elizabeth	Executive VP, General Counsel	Aug 29 '25	Option Exercise	115.67	11,521	1,332,634	22,423	Sep 03 05:13 PM
Forminard Elizabeth	Officer	Aug 29 '25	Proposed Sale	177.20	9,570	1,695,806		Aug 29 03:36 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Option Exercise	101.87	125,824	12,817,691	401,791	Aug 25 07:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 22 '25	Sale	179.21	125,824	22,548,655	275,967	Aug 25 07:12 PM
Duato Joaquin	Officer	Aug 22 '25	Proposed Sale	180.03	125,824	22,652,724		Aug 22 01:58 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Option Exercise	101.87	16,820	1,713,453	30,820	Aug 18 06:19 PM
Wolk Joseph J	Exec VP, CFO	Aug 15 '25	Sale	176.91	16,820	2,975,571	14,000	Aug 18 06:19 PM
Wolk Joseph J	Officer	Aug 15 '25	Proposed Sale	176.91	16,820	2,975,571		Aug 15 03:57 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Jul 17 '25	Sale	163.55	19,137	3,129,830	10,658	Jul 18 04:12 PM
REED JOHN C	Officer	Jul 17 '25	Proposed Sale	163.55	19,137	3,129,831		Jul 17 04:05 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience